Fundz

Biomatter raises $18M in Series A funding led by Astanor to scale its AI-powered enzyme design for global industry leaders.

PRIVATENov 12, 2026

Amount Raised

$18 Million

Round Type

Series A

VilniusManufacturingBiotechnology

Investors

UVC PartnersInventureMetaplanetAstanor

Description

Biomatter, the custom enzyme design company, announced the closing of an oversubscribed $18 million Series A financing. The round was led by Astanor, with participation from UVC Partners, Inventure, and Metaplanet. Biomatter already supplies products including Thermo Fisher Scientific’s Invitrogen™ SuperScript™ V.

Who else raised in Manufacturing and Biotechnology around the same time

Companies in the same sectors as Biomatter that raised within 45 days of this round, from Fundz verified event records.

  • Mosaic Intelligence Labs raised $47M (Seed) on November 10, 2026.
  • altM raised $10M (Series A) on November 5, 2026.
  • FluoRok raised $30M (Series A) on November 5, 2026.
  • Alt Material Innovations Private Limited raised $318K (Series A) on November 4, 2026.
  • MyoPax raised an undisclosed amount (Pre-Seed) on November 4, 2026.
  • IM Cannabis Corp raised $1.2M (Convertible Note) on November 4, 2026.

Who to call at Biomatter, and when

A new round usually means Biomatter is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Biomatter raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Biomatter, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Biomatter. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Biomatter

Location

Vilnius, Vilnius County, Lithuania

About

Biomatter is a custom enzyme design company that utilizes AI to create enzymes for various applications. Their enzymes are already integrated into products used by industry leaders such as Thermo Fisher Scientific. The company focuses on developing solutions that enhance molecular biology and mRNA research. Biomatter is dedicated to scaling its innovative enzyme design capabilities.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Biomatter raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Biomatter's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Biomatter raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.